Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Metab Brain Dis ; 25(2): 219-25, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20424907

ABSTRACT

We evaluated the activities of mitochondrial respiratory chain complexes in the brain of rats after renal ischemia and the effect of administration of the antioxidants N-acetylcysteine (NAC) and deferoxamine (DFX). The rats were divided into the groups: sham (control) or renal ischemia treated with saline, NAC 20 mg/kg, DFX 20 mg/kg or both antioxidants. Complex I activity was inhibited in hippocampus, striatum, prefrontal cortex and cerebral cortex of rats 1 and 6 h after renal ischemia and that the treatment with a combination of NAC and DFX prevented such effect. Complex I activity was not altered in hippocampus, striatum, prefrontal cortex and cerebral cortex of rats 12 h after renal ischemia. Complexes II and III activities were not altered in hippocampus, striatum, prefrontal cortex and cerebral cortex of rats 1, 6 and 12 h after renal ischemia. Complex IV activity was inhibited in hippocampus, striatum, prefrontal cortex and cerebral cortex of rats 1 h after renal ischemia, but the treatment with the combination of NAC and DFX was able to prevent this inhibition. Complex IV activity was not altered in hippocampus, striatum, prefrontal cortex and cerebral cortex of rats 6 and 12 h after renal ischemia. These results suggest that the inhibition of mitochondrial respiratory chain after renal ischemia might play a role in the pathogenesis of uremic encephalopathy.


Subject(s)
Acetylcysteine/pharmacology , Deferoxamine/pharmacology , Electron Transport Complex I/drug effects , Electron Transport/drug effects , Ischemia/metabolism , Ischemia/prevention & control , Kidney Diseases/metabolism , Kidney Diseases/prevention & control , Animals , Cell Respiration/drug effects , Cell Respiration/physiology , Disease Models, Animal , Drug Combinations , Drug Synergism , Electron Transport/physiology , Electron Transport Complex I/metabolism , Free Radical Scavengers/pharmacology , Ischemia/etiology , Kidney Diseases/complications , Male , Rats , Rats, Wistar
2.
Neurosci Lett ; 434(1): 139-43, 2008 Mar 21.
Article in English | MEDLINE | ID: mdl-18304734

ABSTRACT

Encephalopathy may accompany acute or chronic renal failure, and the mechanisms responsible for neurological complications in patients with renal failure are poorly known. Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme. We verified that CK activity was not altered in cerebellum and striatum of rats. CK activity was inhibited in prefrontal cortex and hippocampus of rats 12h after renal ischemia. The treatment with antioxidants prevented such effect. Cerebral cortex was also affected, but in this area CK activity was inhibited 6 and 12h after renal ischemia. Moreover, only NAC or NAC plus DFX were able to prevent the inhibition on the enzyme. Although it is difficult to extrapolate our findings to the human condition, the inhibition of brain CK activity after renal failure may be associated to neuronal loss and may be involved in the pathogenesis of uremic encephalopathy.


Subject(s)
Antioxidants/pharmacology , Brain Diseases, Metabolic/drug therapy , Brain/drug effects , Creatine Kinase/antagonists & inhibitors , Oxidative Stress/drug effects , Uremia/drug therapy , Acetylcysteine/pharmacology , Acetylcysteine/therapeutic use , Animals , Antioxidants/therapeutic use , Brain/enzymology , Brain/physiopathology , Brain Diseases, Metabolic/enzymology , Brain Diseases, Metabolic/physiopathology , Creatine Kinase/metabolism , Deferoxamine/pharmacology , Deferoxamine/therapeutic use , Down-Regulation/drug effects , Down-Regulation/physiology , Ischemia/complications , Kidney Diseases/complications , Male , Nerve Degeneration/drug therapy , Nerve Degeneration/enzymology , Nerve Degeneration/physiopathology , Oxidative Stress/physiology , Rats , Rats, Wistar , Subcellular Fractions , Time Factors , Treatment Outcome , Uremia/enzymology , Uremia/physiopathology
3.
Naunyn Schmiedebergs Arch Pharmacol ; 376(5): 295-300, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18075734

ABSTRACT

Memantine is a non-competitive N-methyl-d-aspartate receptor antagonist, which has been employed in the clinic as a neuroprotective agent for the treatment of several dementias, particularly Alzheimer's disease. In this study, we evaluated pharmacological effects of the acute administration of memantine on memory process. Memory retention scores were evaluated in normal adult Wistar rats injected with saline and memantine (2, 5, 10, and 20 mg/kg, IP) and then subjected to the step-down inhibitory avoidance task, habitation to an open-field apparatus, and object recognition task. The treatment with higher doses of memantine (10 and 20 mg/kg) injected 60 min before or immediately after training-session impaired acquisition and retention of aversive memory in the inhibitory avoidance task. In addition, higher doses of memantine injected 60 min before the first open-field exposure also impaired habituation during the second exposure to the apparatus. No significant differences were observed in the performance of rats treated with memantine, in all doses tested, compared to saline-treated rats in the object recognition task. Notably, we observed that at 5 mg/kg, memantine increased spontaneous locomotion and exploration in the rat open-field test. In conclusion, present findings support the view that memantine at lower doses did not affect memory formation in normal rats, but at high doses memantine, induce hyperlocomotion, which could bias the interpretation of the animal behavior assessed in memory tests.


Subject(s)
Excitatory Amino Acid Antagonists/pharmacology , Memantine/pharmacology , Memory/drug effects , Animals , Avoidance Learning/drug effects , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/administration & dosage , Exploratory Behavior/drug effects , Habituation, Psychophysiologic/drug effects , Injections, Intraperitoneal , Male , Memantine/administration & dosage , Motor Activity/drug effects , Rats , Rats, Wistar , Recognition, Psychology/drug effects
4.
Intensive Care Med ; 33(12): 2165-7, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17668182

ABSTRACT

OBJECTIVE: To evaluate the antidepressant effect of imipramine on depressive symptoms observed in sepsis survivors rats. DESIGN AND SETTING: Prospective, controlled experiment in an animal basic science laboratory. SUBJECTS: Male Wistar rats weighing 300-350 g. INTERVENTIONS: The rats underwent cecal ligation and perforation (CLP; sepsis group) with "basic support" (saline at 50 ml/kg immediately and 12 h after CLP plus ceftriaxone at 30 mg/kg and clindamycin at 25 mg/kg 6, 12, and 18 h after CLP) or sham-operated (control group). After 10 days of recovery rats received intraperitoneal injections of imipramine 10 mg/kg or saline and were subjected to the forced swimming test. MEASUREMENTS AND RESULTS: The observed increase in the immobility time in the forced swimming test in animals subjected to CLP, as a parameter of depressive behavior, was reversed by imipramine. CONCLUSIONS: The depressive symptoms evaluated by forced swimming test had been reversed after imipramine administration. Our data provide evidence that CLP-induced depressive symptoms are sensitive to antidepressants.


Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Depression/drug therapy , Imipramine/therapeutic use , Sepsis/psychology , Animals , Antidepressive Agents, Tricyclic/administration & dosage , Antidepressive Agents, Tricyclic/pharmacology , Brazil , Depression/physiopathology , Imipramine/administration & dosage , Imipramine/pharmacology , Prospective Studies , Rats , Treatment Outcome
5.
Peptides ; 26(12): 2525-9, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16023260

ABSTRACT

The gastrin-releasing peptide receptor (GRPR) has been implicated in the modulation of emotionally-motivated memory. In the present study, we investigated the role of the GRPR on non-emotional, non-associative memory, and anxiety. Adult male Wistar rats were given a systemic injection of the GRPR antagonist [D-Tpi6, Leu(13) psi(CH2NH)-Leu14] bombesin (6-14) (RC-3095) (0.2, 1.0 or 5.0mg/kg) 30 min before exposure to an open field or an elevated plus maze. Habituation to the open field was tested in a retention trial carried out 24 h after the first exposure to the open field. Rats given RC-3095 at the doses of 1.0 or 5.0mg/kg showed impaired habituation. Animals treated with 5.0mg/kg of RC-3095 spent significantly more time in the closed arms of the elevated plus maze. No effects of RC-3095 on locomotion or exploratory behavior were observed. The results implicate the GRPR in the regulation of non-emotional, non-associative memory as well as in anxiety.


Subject(s)
Antineoplastic Agents/administration & dosage , Anxiety , Behavior, Animal/drug effects , Bombesin/analogs & derivatives , Maze Learning/drug effects , Peptide Fragments/administration & dosage , Receptors, Bombesin/antagonists & inhibitors , Animals , Bombesin/administration & dosage , Dose-Response Relationship, Drug , Injections, Intraperitoneal , Locomotion/drug effects , Male , Memory/drug effects , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...